Clarity Pharmaceuticals Advances SECuRE Trial After Positive Interim Results for 67Cu-SAR-bisPSMA

Reuters

Jan 15

<a href="https://laohu8.com/S/CU6.AU">Clarity Pharmaceuticals</a> Advances SECuRE Trial After Positive Interim Results for 67Cu-SAR-bisPSMA

Clarity Pharmaceuticals Ltd. has announced updates on its SECuRE clinical trial evaluating 67Cu-SAR-bisPSMA for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Following an interim data review by the Safety Review Committee $(SRC)$, the trial will proceed with its Cohort Expansion Phase (Phase II) without modifications to the protocol. The interim results, based on data from nine participants as of November 25, 2025, indicate a favorable safety profile and promising efficacy for 67Cu-SAR-bisPSMA. Most participants in the trial were heavily pre-treated and had bone metastases. Clarity Pharmaceuticals intends to progress the product to a registrational Phase III study, with the aim of future commercialization. Results from the current phase have already been collected and assessed by the SRC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN64092) on January 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603766983"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603766983\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603766983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603766983","market":"nz","top_or_hot":-1,"title":"Clarity Pharmaceuticals Advances SECuRE Trial After Positive Interim Results for 67Cu-SAR-bisPSMA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> Advances SECuRE Trial After Positive Interim Results for 67Cu-SAR-bisPSMA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CLRPF\">Clarity Pharmaceuticals Ltd.</a> has announced updates on its SECuRE clinical trial evaluating 67Cu-SAR-bisPSMA for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Following an interim data review by the Safety Review Committee <a href=\"https://laohu8.com/S/SRC\">$(SRC)$</a>, the trial will proceed with its Cohort Expansion Phase (Phase II) without modifications to the protocol. The interim results, based on data from nine participants as of November 25, 2025, indicate a favorable safety profile and promising efficacy for 67Cu-SAR-bisPSMA. Most participants in the trial were heavily pre-treated and had bone metastases. Clarity Pharmaceuticals intends to progress the product to a registrational Phase III study, with the aim of future commercialization. Results from the current phase have already been collected and assessed by the SRC.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN64092) on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clarity Pharmaceuticals Advances SECuRE Trial After Positive Interim Results for 67Cu-SAR-bisPSMA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClarity Pharmaceuticals Advances SECuRE Trial After Positive Interim Results for 67Cu-SAR-bisPSMA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-15 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> Advances SECuRE Trial After Positive Interim Results for 67Cu-SAR-bisPSMA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CLRPF\">Clarity Pharmaceuticals Ltd.</a> has announced updates on its SECuRE clinical trial evaluating 67Cu-SAR-bisPSMA for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Following an interim data review by the Safety Review Committee <a href=\"https://laohu8.com/S/SRC\">$(SRC)$</a>, the trial will proceed with its Cohort Expansion Phase (Phase II) without modifications to the protocol. The interim results, based on data from nine participants as of November 25, 2025, indicate a favorable safety profile and promising efficacy for 67Cu-SAR-bisPSMA. Most participants in the trial were heavily pre-treated and had bone metastases. Clarity Pharmaceuticals intends to progress the product to a registrational Phase III study, with the aim of future commercialization. Results from the current phase have already been collected and assessed by the SRC.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN64092) on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CU6.AU","symbol_name":"CLARITY PHARMACEUTICALS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLb1x75k:1","article_id":"2603766983","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603766983","pubTimestamp":1768485743,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clarity Pharmaceuticals Ltd. has announced updates on its SECuRE clinical trial evaluating 67Cu-SAR-bisPSMA for the treatment of metastatic castration-resistant prostate cancer . Following an interim data review by the Safety Review Committee , the trial will proceed with its Cohort Expansion Phase  without modifications to the protocol. The interim results, based on data from nine participants as of November 25, 2025, indicate a favorable safety profile and promising efficacy for 67Cu-SAR-bisPSMA. Most participants in the trial were heavily pre-treated and had bone metastases. Clarity Pharmaceuticals intends to progress the product to a registrational Phase III study, with the aim of future commercialization. Results from the current phase have already been collected and assessed by the SRC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CU6.AU":"CLARITY PHARMACEUTICALS LTD","BK7096":"制药"},"translate_title":"Clarity Pharmaceuticals在67Cu-SAR-bisPSMA中期结果积极后推进安全试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":0.9},"content_text":"Clarity Pharmaceuticals Advances SECuRE Trial After Positive Interim Results for 67Cu-SAR-bisPSMA\n    \n\nClarity Pharmaceuticals Ltd. has announced updates on its SECuRE clinical trial evaluating 67Cu-SAR-bisPSMA for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Following an interim data review by the Safety Review Committee $(SRC)$, the trial will proceed with its Cohort Expansion Phase (Phase II) without modifications to the protocol. The interim results, based on data from nine participants as of November 25, 2025, indicate a favorable safety profile and promising efficacy for 67Cu-SAR-bisPSMA. Most participants in the trial were heavily pre-treated and had bone metastases. Clarity Pharmaceuticals intends to progress the product to a registrational Phase III study, with the aim of future commercialization. Results from the current phase have already been collected and assessed by the SRC.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN64092) on January 15, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}